BD's Automated Molecular Diagnostics Platform Wins FDA Approval, Initial Test For HPV

Becton Dickinson and Co BDX has received FDA approval for its automated, sample-to-answer, high-throughput BD Cor system along with the BD Onclarity HPV Assay for extended genotyping of human papillomavirus (HPV).
The modular and scalable BD Cor includes an automated sample preparation system, BD Cor PX, and an instrument that automates the BD Onclarity HPV assay, BD Cor GX.
The PX instrument enables the preparation of specimens for testing.
The BD Cor enables the processing of samples directly from liquid-based cytology vials, as well as the creation of molecular aliquot tubes and assay testing, automating labor-intensive and error-prone manual processes.
The Cor has onboard capacity for reagents and samples to provide six to eight hours of system processing.
The BD Cor was initially launched in Europe in 2019.
Related content: Benzinga's Full FDA Calendar.
Price Action: BDX shares are down 0.19% at $247.39 during the market session on the last check Wednesday.